Case Study: 91-Year-Old Colombian Doctor Heals Scalp Squamous Cell Carcinoma with IV CDS in 5 Days



Background
Dr. Hernan, a 91-year-old physician from Colombia, shares his own medical experience as a case study. Three years ago, squamous cell carcinoma was discovered on his scalp. The tumor was surgically removed, but the underlying bone site was not adequately addressed.
Over time, a CT scan revealed that the cancer had already penetrated through the second bone layer and was very close to the dura mater (the protective membrane covering the brain). Multiple examinations, including MRIs and consultations with oncologists and dermatologists, confirmed that the cancer had not metastasized to other organs.
Surgeries and radiotherapy were suggested, but the cancer continued to invade the entire scalp, parietal, frontal, and occipital bones. Dr. Hernan, as a medical professional, determined that this case required systemic or radiological treatment, never surgical.
With no conventional options available and time running out, he decided to treat himself with intravenous chlorine dioxide.
Protocol Applied
- IV CDS: 30 cubic centimeters (30ml) in one IV bag, administered twice daily for 5 days
- After initial phase: 30ml daily, both intravenously and orally
- Total IV treatment duration: 10 days
- Oral CDS: Continued daily beyond IV treatment
Results
The transformation was described by the patient as a miracle. What had been a wound covering the entire scalp was perfectly healed by the fifth day of treatment.
Daily photographs were taken documenting the complete resolution. Dr. Hernan reports that he continues to take CDS daily and will continue doing so for the rest of his life.
The Patient's Message
"You cannot imagine the miracle. I thank you infinitely for saving so many lives. You are the person who has saved the most lives in the long history of humanity. You deserve a statue like the Statue of Liberty."
- Dr. Hernan, 91-year-old physician, Colombia
Source
Personal testimonial from Dr. Hernan, Colombian physician, via Telegram. Published with permission.